Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem... see more

NDAQ:IPA - Post Discussion

View:
Post by mercedesman on Nov 26, 2021 11:14am

VOC's

Robust and comprehensive new vaccines will be needed to counter the likely emergence of this "Nu" variant of concern...that may largely (or to some extent) evade existing vaccines

This is where IPA should start to shine (in rounds 2, 3 and 4 of vaccines). IMO this Covid prolem will be with us for a decade or more.

The big boys (vacciine makers) need new weapons to do battle.

Will IPA be one of the weapon makers?  I'm betting a decent amount that they will be.

Do we have to go through a lot of overhead (underwater investors?) over the next little while?  You bet !

But they just need one or two hits to cut through the overburden like a hot knife through butter.  The need for their products is growing, not shrinking (unfortunately and fortunately)

GLTA

MM
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities